久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

  • Cullinan Oncology completes $98.5m Series B financing pharmaceutical-business-review
    June 09, 2020
    C?ullinan Oncology, LLC announced today the closing of a $98.5 million Series B financing, which will be used to support ongoing clinical trials across its small molecule and biologics portfolio.
  • Taiho Pharmaceutical licences lung cancer drug to Cullinan Oncology pharmaceutical-technology
    February 20, 2019
    Japan-based Taiho Pharmaceutical has signed an agreement to licence its epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor candidate TAS6417 for lung cancer to Cullinan Oncology....

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service